Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Biomarker Development for Muscular Dystrophies

Massachusetts General Hospital · with Boston Children's Hospital, Wake Forest University · NCT05019625

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 5+ · All sexes
Healthy volunteers
Accepted
Study type
Observational
Target enrollment
465
US sites recruiting
4
Study start
February 20, 2015
Record last updated
November 24, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Current methods of measuring the response to new treatments for muscular dystrophies involve the examination of small pieces of muscle tissue called biopsies. The investigators are interested in finding less invasive methods that reduce the need for muscle biopsies. The purpose of this research is to learn about the possibility of detecting and measuring the activity and severity of muscular dystrophies by examining a urine sample and a blood sample, and some muscles in the arms and legs using tests called ultrasound and electrical impedance myography; both tests are painless and non-invasive. The information that is gathered from this study may help to evaluate, prevent, diagnose, treat, and improve the understanding of human muscle diseases.

Conditions: Myotonic Dystrophy; Duchenne Muscular Dystrophy; Becker Muscular Dystrophy; Facioscapulohumeral Muscular Dystrophy

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Subjects with DM1 or DM2 based on genetic testing and/or clinical criteria (some subjects who have positive genetic testing may be asymptomatic, while other subjects who show characteristic clinical features may have declined to have genetic testing done). Control non-DM subjects are unknown to have DM or any other muscular dystrophy by history and may have had no genetic testing.
  • Able to provide informed consent or assent for participation in the study.
  • Demographic characteristics for single biofluid collection: Males and females age 5 years and older.
  • Demographic characteristics for serial biofluid and muscle function testing: Males and females age 14 years and older with DM1.
  • Demographic characteristics for biofluid and muscle biopsy: Males and females, ages 18-65 years.

Demographic characteristics for single biofluid collection, ultrasound, and myography: Males and females age 14 years and older.

Exclusion Criteria

  • Medical history of any of the following. State of immunosuppression; coagulopathy; pre-existing liver or kidney disease; documented HIV positive; documented hepatitis B and/or C positive.
  • Medications and other drugs. Use of anti-platelet drugs within 7 days prior to blood draw or biopsy; use of anticoagulants within 60 days prior to blood draw or biopsy; active drug or alcohol use or dependence that, in the opinion of the biopsy surgeon, would interfere with post-procedure wound care.
  • Other. Inability or unwillingness of the subject to give written informed consent.

Recruiting US locations

  • Brigham and Women's Hospital

    Boston, MA 02115

    Site contact: Louis Beers · lbeers@bwh.harvard.edu

  • Massachusetts General Hospital

    Boston, MA 02129

    Site contact: Tamkin Shahraki, MD · 617-726-7506 · tshahraki@mgh.harvard.edu

  • Wake Forest University

    Winston-Salem, NC 27157

    Site contact: Constance Linville · 336-716-4568 · clinvill@wakehealth.edu

  • University of Pittsburgh

    Pittsburgh, PA 15213

    Site contact: Kerry M. Oddis, RN, CCRC · 412-692-4918 · kmoddis@upmc.edu

Study contacts (from the official record)

  • Tamkin Shahraki, MD · 617-726-7506 · tshahraki@mgh.harvard.edu
Biomarker Development for Muscular Dystrophies (NCT05019625) | Bored Studies